We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Cancer immunotherapy shows promise in multiple tumor types.
- Authors
Heger, Monica
- Abstract
The article discusses an immunotherapy drug Yervoy (ipilimumab) that had effective effect on late-stage melanoma. It states that this drug functions by blocking surface protein cytotoxic T lymphocyte antigen 4 (CTLA-4). It further states that in the meeting of American Society of Clinical Oncology (ASCO) the researchers showed that blocking a protein called programmed death 1 (PD-1) reduces the tumor mass. It mentions that CTLA-4 binding occurs in T cells whereas PD-1 occurs in tumor cells.
- Subjects
MELANOMA immunotherapy; IPILIMUMAB; CELL surface antigens; AMERICAN Society of Clinical Oncology; T cells
- Publication
Nature Medicine, 2012, Vol 18, Issue 7, p993
- ISSN
1078-8956
- Publication type
Article
- DOI
10.1038/nm0712-993